INTRODUCTION: Few cases of pulmonary toxicity related to epidermal growth factor receptor-targeted agents have been described. CASE PRESENTATION: We report a case of a 63-year-old white male with stage IV non-small cell lung cancer treated with erlotinib who developed a interstitial lung disease. CONCLUSION: Respiratory symptoms during treatment with erlotinib should alert clinicians to rule out pulmonary toxicity. Early erlotinib withdrawal and corticoid administration were successful.
No takes yet. Share an insight, caveat, or question.
Castillo et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: